巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Actinium Pharmaceuticals

ATNM
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Actinium Pharmaceuticals - 延遲價格・最後更新於 14/01 12:14
最高位
5.820
最低位
5.600
開市價
--
前收市價
5.675
成交量(千)
2.22
成交額(百萬)
0.07
買入
--
賣出
--
每手股數
--
市值(百萬)
127.12
市盈率
--
息率
--
差價
--
52週高低
10.300 - 5.570
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Actinium Pharmaceuticals
證券代碼
ATNM.US
所屬板塊
Biotechnology
公司業務
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
發行量
19245638
公司總部
275 Madison Avenue, 7th Floor
公司網址
https://www.actiniumpharma.com
公司電郵
investorrelations@actiniumpharma.com
公司電話
+1 646 677-3870
暫無內容

關於

Actinium Pharmaceuticals(ATNM.US)所屬的行業板塊為Biotechnology。
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
詳細公司背景可參考: https://www.actiniumpharma.com